The rising prevalence of overweight and obesity among adults in Malaysia is a growing concern, with statistics revealing that ...

The Allurion swallowable intragastric balloon offers a safe, effective and minimally invasive method of losing weight.

Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.

Allurion (ALUR) stock soared 70% after the company announced it is planning to conduct a clinical study of its gastric balloon weight-loss product in combination with GLP-1 drugs.

The Allurion intragastric balloon (IGB) is inserted through the mouth into the patient's stomach endoscopically before being expanded with 550 ... it remains in the stomach for four months. After that ...

U.S. stocks closed higher on Thursday, with the S&P 500 reaching record highs after President Donald Trump ... on Friday ahead of its earnings before the opening bell. Analysts expect it to ...

Shares in the NYSE-listed company rose 77% at market open on 24 January 2025, compared to a market close, which occurred shortly after Allurion made the announcement. It is the highest price the ...

Allurion Technologies (NYSE:ALUR) climbed 200% in the morning hours on Friday, adding to its strong post-market gains yesterday, even after the weight loss product developer announced plans to ...

Allurion Technologies ... to the Company from this offering are expected to be approximately $7.4 million, before deducting the placement agent’s fees and other offering expenses payable ...